ArticleKidney medicine2024

Ravulizumab in Atypical Hemolytic Uremic Syndrome: An Analysis of 2-Year Efficacy and Safety Outcomes in 2 Phase 3 Trials.

Bradley P Dixon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.